These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31060315)

  • 1. Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4.
    Marascio N; Mazzitelli M; Pavia G; Giancotti A; Barreca GS; Costa C; Pisani V; Greco G; Serapide F; Trecarichi EM; Casalinuovo F; Liberto MC; Matera G; Torti C
    Cells; 2019 May; 8(5):. PubMed ID: 31060315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
    Kozuka R; Hai H; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
    J Viral Hepat; 2018 May; 25(5):535-542. PubMed ID: 29274188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
    Ahmed H; Elgebaly A; Abushouk AI; Hammad AM; Attia A; Negida A
    Antivir Ther; 2017; 22(5):369-379. PubMed ID: 27588749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
    Zeuzem S; Mizokami M; Pianko S; Mangia A; Han KH; Martin R; Svarovskaia E; Dvory-Sobol H; Doehle B; Hedskog C; Yun C; Brainard DM; Knox S; McHutchison JG; Miller MD; Mo H; Chuang WL; Jacobson I; Dore GJ; Sulkowski M
    J Hepatol; 2017 May; 66(5):910-918. PubMed ID: 28108232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
    Bourlière M; Adhoute X; Ansaldi C; Oules V; Benali S; Portal I; Castellani P; Halfon P
    Expert Rev Gastroenterol Hepatol; 2015; 9(12):1483-94. PubMed ID: 26595560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.
    Childs K; Davis C; Cannon M; Montague S; Filipe A; Tong L; Simmonds P; Smith D; Thomson EC; Dusheiko G; Agarwal K
    J Hepatol; 2019 Dec; 71(6):1099-1105. PubMed ID: 31400349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir.
    Wyles D; Mangia A; Cheng W; Shafran S; Schwabe C; Ouyang W; Hedskog C; McNally J; Brainard DM; Doehle BP; Svarovskaia E; Miller MD; Mo H; Dvory-Sobol H
    Antivir Ther; 2018; 23(3):229-238. PubMed ID: 28650844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
    Surendra M; Raju SB; Sridhar N; Vijay Kiran B; Rajesh G; Anvesh G; Raju N
    Hemodial Int; 2018 Apr; 22(2):217-221. PubMed ID: 28972699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
    Rockstroh JK; Bhagani S; Hyland RH; Yun C; Dvory-Sobol H; Zheng W; Brainard DM; Ingiliz P; Lutz T; Boesecke C; Nelson M
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):347-353. PubMed ID: 28397698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors.
    Toyodome A; Mawatari S; Eguchi H; Takeda M; Kumagai K; Taniyama O; Ijuin S; Sakae H; Tabu K; Oda K; Ikeda M; Ido A
    Sci Rep; 2024 Jul; 14(1):16363. PubMed ID: 39013947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
    Razafindrazoto CI; Rasolonjatovo AS; Rabenjanahary TH; Randriamifidy NH; Rakotozafindrabe ALR; Razafimahefa SH; Ramanampamonjy RM
    Int J Infect Dis; 2021 Jun; 107():166-169. PubMed ID: 33895411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.
    Rezaee-Zavareh MS; Hesamizadeh K; Behnava B; Alavian SM; Gholami-Fesharaki M; Sharafi H
    Ann Hepatol; 2017; 16(2):188-197. PubMed ID: 28233739
    [No Abstract]   [Full Text] [Related]  

  • 17. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of
    Brandão R; Marcelino R; Gonçalves F; Diogo I; Carvalho A; Cabanas J; Costa I; Brogueira P; Ventura F; Miranda A; Mansinho K; Gomes P
    Viruses; 2018 Apr; 10(5):. PubMed ID: 29701642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
    Curry MP; Tapper EB; Bacon B; Dieterich D; Flamm SL; Guest L; Kowdley KV; Lee Y; Milligan S; Tsai N; Younossi Z; Afdhal NH
    Aliment Pharmacol Ther; 2017 Sep; 46(5):540-548. PubMed ID: 28691377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.